Skip to main content

Table 1 Demographic and clinical characteristics of patients

From: Hyaluronic acid and platelet-rich plasma, a new therapeutic alternative for scleroderma patients: a prospective open-label study

 

Gender

Age

SSc type

Disease duration

Autoantibodies

DMARDs

Patient 1

F

38

Limited

7

ANA, anti-CENP-B

MMF, HCQ

Patient 2

F

62

Limited

7

ANA

RTX

Patient 3

F

53

Diffuse

4

ANA, anti-Scl70

AZA, HCQ

Patient 4

F

47

Diffuse

8

ANA, anti-Scl70

RTX

Patient 5

F

38

Diffuse

2

ANA, anti-Scl70

AZA

Patient 6

F

45

Diffuse

9

ANA, anti-CENP-B

HCQ

Patient 7

F

33

Diffuse

9

ANA

MMF

Patient 8

F

51

Diffuse

5

ANA, anti-Scl70

MMF

Patient 9

F

41

Diffuse

2

ANA

HCQ

Patient 10

F

40

Diffuse

7

ANA, anti-Scl70

MMF, HCQ

  1. MMF mycophenolate mofetil, HCQ hydroxychloroquine, RTX rituximab, AZA azathioprine